Pfizer Stock Surges: Vanguard Buys, Analyst Upgrades & TALZENNA Wins
Pfizer’s latest moves: Vanguard’s big buy, Guggenheim’s upgraded target, TALAPRO‑3 results, 6.3% dividend yield – a mixed but bullish snapshot for investors.
2 minutes to read
PFIZER INC
Pfizer’s Phase‑3 Lyme Vaccine & Prostate Trial Boosts Outlook; Stock Surges 6.6% YTD
Pfizer’s latest news: Phase 3 Lyme vaccine shows 73% efficacy, prostate‑cancer trial could boost shares to $36, and a 6.5% dividend keeps investors bullish.
3 minutes to read
Pfizer’s Lyme Vaccine Breaks 73% Efficacy Milestone: What Investors Should Know
Pfizer’s 73%‑effective Lyme vaccine hits Phase 3 milestones, sparking regulatory plans but tempered market response as investors weigh commercial prospects and competitive challenges.
3 minutes to read
Pfizer Sees Heavy Institutional Buying Ahead of 2028 Medicare Negotiations
Pfizer’s 2026 investor activity shows heavy institutional buying while Medicare price talks loom, hinting at future revenue impacts.
2 minutes to read
Pfizer’s 2026 Guidance Misses, Boosting Bearish Sentiment and Uncertain Growth Outlook
Pfizer’s 2026 earnings miss sparks a sharp shift to “hold” and rising bearish sentiment, as price‑control pressures and safety concerns threaten the pharma giant’s growth legacy.
3 minutes to read